Announcement of Nikkei Biotech ONLINE article on the Phase II clinical trial for cutaneous angiosarcoma

We are pleased to announce that an article on the “Phase II investigator-initiated clinical trial to investigate the safety and efficacy of the combination therapy of paclitaxel and RS5614 for cutaneous angiosarcoma,” which we are conducting with seven medical institutions including Tohoku University, has been published in Nikkei Biotech ONLINE.

Nikkei Biotech ONLINE article
https://bio.nikkeibp.co.jp/atcl/news/p1/25/06/20/13439/

Our related information: “Announcement of completion of patient registration in a Phase II clinical trial with paclitaxel and PAI-1 inhibitor (RS5614) combination therapy for cutaneous angiosarcoma” (timely disclosed on June 20, 2025)
https://contents.xj-storage.jp/xcontents/AS09109/80fa9e73/3115/49c0/a92e/8d5406038978/140120250620594600.pdf